Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

MyMD Pharmaceuticals Inc

Healthcare US MYMD

NoneUSD
0.00(0%)

Last update at 2024-10-23T19:00:25.284737Z

Day Range

--
LowHigh

52 Week Range

1.9763.90
LowHigh

Fundamentals

  • Previous Close 1.33
  • Market Cap4.62M
  • VolumeNone
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-28.18291M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-9.27

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -15.19734M -29.88904M -9.48782M -3.88825M -10.84903M
Minority interest - - - - -
Net income -15.11191M -29.88014M -10.67968M -3.88825M -10.84903M
Selling general administrative 6.22M 21.46M 5.81M 3.73M 5.67M
Selling and marketing expenses - - 0.02M 0.24M 1.78M
Gross profit 0.00000M 0.00000M 0.00000M 0.48M 0.13M
Reconciled depreciation - 0.00000M 0.02M - -
Ebit -15.28276M -28.80971M -9.48797M -3.88825M -10.84903M
Ebitda -15.19877M -28.19234M -8.27763M -3.81419M -10.61455M
Depreciation and amortization 0.08M 0.62M 1.21M 0.07M 0.23M
Non operating income net other - - 0.13M - -
Operating income -15.28276M -28.80971M -9.48797M -3.80460M -8.55541M
Other operating expenses 15.28M 28.20M 8.30M 5.38M 10.22M
Interest expense -0.08543M 0.61M 1.19M 0.00000M 0.00000M
Tax provision 0.00000M 0.00000M 0.00000M - -
Interest income 0.08M 0.00891M 0.17M 0.10M 0.14M
Net interest income 0.08M -0.59955M -1.19172M - -
Extraordinary items - - -5.42840M -0.50695M -
Non recurring - - - - -
Other items - - - - -
Income tax expense -0.08543M -0.00891M 1.19M -0.08365M -2.29363M
Total revenue 0.00000M 0.00000M 0.00000M 1.58M 1.67M
Total operating expenses 15.28M 28.20M 8.30M 4.28M 8.68M
Cost of revenue 0.00000M 0.00000M 0.00000M 1.10M 1.54M
Total other income expense net 0.09M -1.07934M 0.00014M -0.08365M -2.29363M
Discontinued operations - - -5.42840M - -
Net income from continuing ops -15.19734M -29.88904M -12.15221M - -
Net income applicable to common shares - -29.88904M -8.93046M -9.63892M -18.06513M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 17.86M 17.54M 24.81M 0.68M 10.88M
Intangible assets - - - - 0.17M
Earning assets - - - - -
Other current assets 0.89M 0.57M 1.11M 0.31M 0.39M
Total liab 5.09M 2.84M 1.17M 5.93M 1.53M
Total stockholder equity 12.77M 14.70M 23.65M -5.25703M 9.36M
Deferred long term liab - - - - -
Other current liab 0.96M 0.35M 0.12M 2.26M 0.87M
Common stock 0.00202M 108.31M 102.06M 0.00400M 128.92M
Capital stock 0.15M 108.45M 102.21M 0.00400M -
Retained earnings -101.97707M -93.75890M -78.56157M -48.67252M -119.58313M
Other liab - - 0.03M - -
Good will 10.50M 10.50M 10.50M 0.00000M -
Other assets 0.00000M - - - 0.37M
Cash 2.68M 0.75M 0.56M 0.15M 0.52M
Cash and equivalents - - - - -
Total current liabilities 4.99M 2.77M 1.04M 2.35M 1.53M
Current deferred revenue 0.27M - - -2.26329M -
Net debt -2.63214M -0.60737M -0.40682M 3.98M -0.51744M
Short term debt 0.05M 0.07M 0.05M 0.55M -
Short long term debt - - - 0.07M -
Short long term debt total 0.05M 0.14M 0.15M 4.13M -
Other stockholder equity 114.20M 0.14M 0.14M 43.41M 2.12M
Property plant equipment - 0.14M 0.15M 0.53M 0.03M
Total current assets 5.82M 5.40M 12.67M 0.15M 10.31M
Long term investments 1.50M 1.50M 1.50M 0.00000M -
Net tangible assets - 4.05M 13.00M -4.09321M -1.74470M
Short term investments 2.24M 4.09M 11.00M 16.72M 9.16M
Net receivables - - - 1.20M 0.04M
Long term debt - - - 3.53M -
Inventory - - - -1.50514M 0.20M
Accounts payable 3.72M 2.36M 0.87M 1.80M 0.66M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -0.00202M -0.14452M - -0.14452M -2.10330M
Additional paid in capital - - - - -
Common stock total equity - - - 171.60M 128.92M
Preferred stock total equity - - - 0.14M -
Retained earnings total equity - - - -137.16374M -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.00000M 1.50M 1.50M - 0.37M
Deferred long term asset charges - - - - -
Non current assets total 12.05M 12.14M 12.15M 0.53M 0.57M
Capital lease obligations 0.05M 0.14M 0.15M 0.53M -
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments 6.91M 19.85M -8.75747M 18.47M 18.47M
Change to liabilities 0.00000M -4.26896M 0.15M 0.49M -0.31800M
Total cashflows from investing activities - 19.85M -8.75747M -3.94063M -0.35969M
Net borrowings - -1.11631M 2.55M 1.93M 5.20M
Total cash from financing activities 5.55M 0.07M 4.68M 6.97M 9.11M
Change to operating activities - -0.91290M 0.18M -0.00154M 0.02M
Net income -15.19734M -29.88904M -9.48782M -3.88825M -10.84903M
Change in cash 0.19M 0.41M 0.01M -0.04922M 0.24M
Begin period cash flow 0.56M 0.15M 0.13M 0.68M 0.44M
End period cash flow 0.75M 0.56M 0.15M 0.63M 0.68M
Total cash from operating activities -12.27007M -19.51647M -4.66355M -3.07428M -8.51737M
Issuance of capital stock 5.55M 0.00000M 1.98M - -
Depreciation - 0.00000M 0.02M 0.07M 0.23M
Other cashflows from investing activities - - -8.75747M -3.94063M -0.29147M
Dividends paid - 0.00302M - - -
Change to inventory - - 0.20M 0.01M 0.08M
Change to account receivables - - 0.04M 0.13M 0.63M
Sale purchase of stock - - 1.74M 4.82M 9.11M
Other cashflows from financing activities 6.91M 3.14M 0.95M 0.00006M 7.16M
Change to netincome - 14.95M 2.86M 3.58M 10.75M
Capital expenditures 0.00000M 0.00000M 0.00000M 0.00000M 0.07M
Change receivables - - 0.04M - -
Cash flows other operating - - -11.66989M - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - 17.99M - -
Change in working capital 2.23M -5.18186M 0.57M 4.08M -2.85522M
Stock based compensation 0.34M - 0.40M 0.40M 0.05M
Other non cash items 0.36M 15.55M 4.23M -3.74469M 4.91M
Free cash flow -12.27007M -19.51647M -4.66355M -3.07428M -8.58558M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
MYMD
MyMD Pharmaceuticals Inc		 - -% - - - - 0.42 -0.0274
NVO
Novo Nordisk A/S		 -0.79 1.81% 42.96 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -0.6937 1.57% 43.50 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 5.09 1.15% 446.83 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 6.72 1.07% 635.45 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

MyMD Pharmaceuticals, Inc., a clinical development stage pharmaceutical company, focuses on developing various therapeutic platforms to treat the aging and age-related and autoimmune diseases, and chronic pain, anxiety, and sleep disorders. The company is developing MYMD-1, a drug platform based on a clinical stage small molecule that regulates the immunometabolic system and its pro-inflammatory cytokines to treat autoimmune diseases and age-related illnesses, and a Phase 2 clinical trial for multiple sclerosis, diabetes, inflammatory bowel diseases, and rheumatoid arthritis. It is also developing Supera-CBD, a synthetic analog of cannabidiol for treating epilepsy, pain, and anxiety/depression. The company was founded in 2014 and is headquartered in Baltimore, Maryland.

MyMD Pharmaceuticals Inc

855 North Wolfe Street, Baltimore, MD, United States, 21205

Key Executives

Name Title Year Born
Dr. Christopher C. Chapman Jr., M.D. Pres, Chief Medical Officer & Director 1953
Mr. Paul M. Rivard Esq. Exec. VP of Operations & Gen. Counsel 1971
Dr. Adam Kaplin M.D., Ph.D. Chief Scientific Officer 1967
Mr. Ian Rhodes CPA Interim Chief Financial Officer 1973
Ms. Katherine Whartenby Ph.D. Chief Scientific Advisor & Member of Advisory Board NA
Dr. Christopher C. Chapman Jr., M.D. President, Chief Medical Officer & Director 1953
Dr. Adam Kaplin M.D., Ph.D. Chief Scientific Officer 1968
Dr. Jenna Brager M.S., Ph.D., R.N. Executive Vice President of Drug Development NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.